Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip Prothesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, 18 years of age or older.~* Written informed consent~* Subjects with cemented or not cemented total hip prothesis (for primitive or secondary coxarthrosis)~* Painful aseptic loosening~* Subject has pain 4 or greater on a 10 point Visual Pain Rating scale~* For subject woman of reproductive age, they must use reliable method(s) of contraception and/or abstinence, for the duration of therapeutic product exposure.~Exclusion Criteria:~* Subjects with septic loosening of hip prosthesis~  . Subjects with bilateral disease~* Subjects with implant mobility associated with pre-operative and intraoperative loosening~* Subjects under anti-osteoporotic treatment~* Subjects having stopped a biphosphonate traetment for less than one year~* Subjects with known allergy or sensitivity to any of the components in the study medication.~  * Subjects with Hypocalcemia~ * Females who are pregnant, breast-feeding, or planning a pregnancy during the study or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.~ * Subjects with severe kidney failure ( creatinine \< 30 ml/min)).~ * Subjects participation in another research study~ * Subjects with previous osteonecrosis of the jaw

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Risedronate (Type: EXPERIMENTAL): Patients take an oral tablet of Risedronate 75 mg, 2 consecutive days per month during 18 months.
- Placebo (Type: PLACEBO_COMPARATOR): Patients take an oral tablet of Placebo, 2 consecutive days per month during 18 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).